European Medicines Agency Gave Positive Opinion on Novo Nordisk's (NVO) Ozempic Label

Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A/S (NYSE:NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion to update the Ozempic label.

The update is based on the new data from the STRIDE trial, which studied people with type 2 diabetes and peripheral artery disease (PAD). The STRIDE trial showed that once-weekly semaglutide improved how far people with PAD and type 2 diabetes could walk. It also improved symptoms and quality of life compared to a placebo.

Novo Nordisk A/S (NYSE:NVO) says that, if approved by the European Commission, Ozempic will be the only GLP-1 drug proven to reduce risks of cardiovascular death, heart attack, stroke, major kidney events, and improve walking in people with type 2 diabetes. Management is expecting the label update in about two months.

Novo Nordisk A/S (NYSE:NVO) is an international healthcare company primarily focused on diabetes care and treatment.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.